Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Revenue Grows 16 Percent in Second Quarter

NEW YORK, Aug. 13 (GenomeWeb News) - Stratagene, a developer, manufacturer and marketer of life science research and immunodiagnostics products, announced today that its second quarter revenues grew 16 percent to $19.7 million, compared with $17.0 million in the second quarter of 2003.

 

For the second quarter, Stratagene generated a net income of $1.5 million, or $.08 per diluted share, an increase compared with $1.1 million, or $.07 per diluted share in the same quarter of last year.

 

Research and development spending during the three months ending June 30 totaled $2.81 million - up compared to $2.75 million during the same period last year.

 

Results for the second quarter and first half of 2004 were impacted by one-time expenses of $2.4 million associated with the merger of the company with Hycor Biomedical on  June 3 .

 

The company's cash, cash equivalents and marketable securities were $8.5 million

during the second quarter, and total assets were $85.7 million.

 

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.